BiomX (PHGE) 10-Q 13 Aug 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 11, 2020
Document and Entity Information [Abstract]
Entity Registrant Name	Biomx Inc.
Entity Central Index Key	0001739174
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		23,145,964
Entity File Number	001-38762
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	DE

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 59,377	$ 72,256
Restricted cash	853	154
Short-term deposits	10,390	10,003
Related party		50
Other current assets	821	2,068
Total current assets	71,441	84,531
Non-current assets
Lease deposit		5
Property and equipment, net	2,092	1,881
In-process research and development ("R&D")	3,798	4,556
Operating lease right-of-use asset	979	1,148
Total non-current assets	6,869	7,590
Total asset	78,310	92,121
Current liabilities
Trade account payables	1,282	3,253
Other account payables	1,830	2,596
Current portion of lease liabilities	369	375
Total current liabilities	3,481	6,224
Non-current liabilities
Lease liabilities - net of current portion	665	856
Contingent liabilities	643	585
Total non-current liabilities	1,308	1,441
Commitments and Contingent Liabilities
Shareholders' equity
Common stock, $0.0001 par value ("Common Stock"); Authorized - 60,000,000 shares as of June 30, 2020 and December 31, 2019. Issued - 23,145,964 as of June 30, 2020 and 22,862,835 as of December 31, 2019. Outstanding - 23,140,264 shares as of June 30, 2020 and 22,862,835 as of December 31, 2019	2	2
Additional paid in capital	127,798	126,626
Accumulated deficit	(54,279)	(42,172)
Total shareholders' equity	73,521	84,456
Total liabilities and shareholders' equity	$ 78,310	$ 92,121

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, authorized	60,000,000	60,000,000
Common stock, issued	23,145,964	22,862,835
Common stock, outstanding	23,140,264	22,862,835

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Research and development expenses, net	$ 4,097	$ 2,864	$ 8,005	$ 5,600
General and administrative expenses	2,297	1,203	4,355	2,190
Operating loss	6,394	4,067	12,360	7,790
Financial income, net	(188)	(289)	(253)	(787)
Net Loss	$ 6,206	$ 3,778	$ 12,107	$ 7,003
Basic and diluted loss per share of Common Stock	$ 0.27	$ 2.50	$ 0.53	$ 4.68
Weighted average number of shares of Common Stock outstanding, basic and diluted	22,969,075	2,005,047	22,944,482	2,005,047

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock		Additional paid in capital	Accumulated deficit	Preferred A Shares (pre-merger-BiomX Ltd.)		Preferred B Shares (pre-merger-BiomX Ltd.)		Total
Balance at Dec. 31, 2018		[1]	$ 64,410	$ (21,609)	$ 1		$ 1		$ 42,803
Balance, shares at Dec. 31, 2018	2,307,871	[2]			7,543,831	[1]	5,170,357	[1]
Issuance of shares			1,800					[1]	1,800
Issuance of shares, shares		[2]				[1]	308,628	[1]
Share-based payment			304						304
Net loss				(3,225)					(3,225)
Balance at Mar. 31, 2019		[1]	66,514	(24,834)	$ 1		$ 1		41,682
Balance, shares at Mar. 31, 2019	2,307,871	[2]			7,543,831	[1]	5,478,985	[1]
Balance at Dec. 31, 2018		[1]	64,410	(21,609)	$ 1		$ 1		42,803
Balance, shares at Dec. 31, 2018	2,307,871	[2]			7,543,831	[1]	5,170,357	[1]
Share-based payment									631
Balance at Jun. 30, 2019		[1]	66,841	(28,612)	$ 1		$ 1		38,231
Balance, shares at Jun. 30, 2019	2,307,871	[2]			7,543,831	[1]	5,478,985	[1]
Balance at Mar. 31, 2019		[1]	66,514	(24,834)	$ 1		$ 1		41,682
Balance, shares at Mar. 31, 2019	2,307,871	[2]			7,543,831	[1]	5,478,985	[1]
Share-based payment			327						327
Net loss				(3,778)					(3,778)
Balance at Jun. 30, 2019		[1]	66,841	(28,612)	$ 1		$ 1		38,231
Balance, shares at Jun. 30, 2019	2,307,871	[2]			7,543,831	[1]	5,478,985	[1]
Balance at Dec. 31, 2019	$ 2		126,626	(42,172)					84,456
Balance, shares at Dec. 31, 2019	22,862,835
Exercise of options		[1]	106						106
Exercise of options, shares	57,325
Share-based payment			337						337
Net loss				(5,901)					(5,901)
Balance at Mar. 31, 2020	$ 2		127,069	(48,073)					78,998
Balance, shares at Mar. 31, 2020	22,920,160
Balance at Dec. 31, 2019	$ 2		126,626	(42,172)					$ 84,456
Balance, shares at Dec. 31, 2019	22,862,835
Exercise of options, shares									277,429
Share-based payment									$ 1,014
Balance at Jun. 30, 2020	$ 2		127,798	(54,279)					73,521
Balance, shares at Jun. 30, 2020	23,140,264
Balance at Mar. 31, 2020	$ 2		127,069	(48,073)					78,998
Balance, shares at Mar. 31, 2020	22,920,160
Exercise of options		[1]	52						52
Exercise of options, shares	220,104
Share-based payment			677						677
Net loss				(6,206)					(6,206)
Balance at Jun. 30, 2020	$ 2		$ 127,798	$ (54,279)					$ 73,521
Balance, shares at Jun. 30, 2020	23,140,264
[1]	Less than $1.
[2]	Number of shares has been retroactively adjusted based on the equivalent number of shares received by the accounting acquirer in the Recapitalization Transaction consummated on October 28, 2019 (refer to Note 1).

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
CASH FLOWS - OPERATING ACTIVITIES
Net loss	$ (12,107)	$ (7,003)
Adjustments required to reconcile cash flows used in operating activities
Depreciation and amortization	1,016	205
Share-based compensation	1,014	631
Revaluation of contingent liabilities	58	14
Changes in operating assets and liabilities:
Other receivables	1,252	(93)
Trade account payables	(1,896)	319
Other account payables	(766)	94
Operating lease liabilities	(28)
Related parties	50	(95)
Net cash used in operating activities	(11,407)	(5,928)
CASH FLOWS - INVESTING ACTIVITIES
Decrease (Increase) in short-term deposits	(387)	12,438
Purchase of property and equipment	(469)	(766)
Net cash provided by (used in) investing activities	(856)	11,672
CASH FLOWS – FINANCING ACTIVITIES
Issuance of preferred shares, net		1,800
Outflows in connection with current assets and liabilities acquired in Recapitalization Transaction	(75)
Exercise of stock options	158
Net cash provided by financing activities	83	1,800
Increase (decrease) in cash and cash equivalents and restricted cash	(12,180)	7,544
Cash and cash equivalents and restricted cash at the beginning of the period	72,410	8,693
Cash and cash equivalents and restricted cash at the end of the period	60,230	16,237
Supplemental non-cash transactions:
Recognition of right-of-use asset and lease liability upon adoption of ASU 2016-02		$ 662

General

General	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL	NOTE 1 – GENERAL A. General information: BiomX Inc. (together with its subsidiaries, BiomX Ltd. and RondinX Ltd., the "Company" or "BiomX", formerly known as Chardan Healthcare Acquisition Corp.) was incorporated as a blank check company on November 1, 2017, under the laws of the state of Delaware, for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. On July 16, 2019, the Company entered into a merger agreement with BiomX Ltd. ("BiomX Israel"), a company incorporated under the laws of Israel, CHAC Merger Sub Ltd. ("Merger Sub") and Shareholder Representative Services LLC ("SRS"), as amended on October 11, 2019, pursuant to which, among other things, BiomX Israel merged with Merger Sub, with BiomX Israel being the surviving entity in accordance with the Israeli Companies Law, 5759-1999, as a wholly owned direct subsidiary of BiomX Inc. On October 28, 2019, the Company acquired 100% of the outstanding shares of BiomX Israel (the "Recapitalization Transaction"). Pursuant to the aforementioned merger agreement, in exchange for all of the outstanding shares of BiomX Israel, the Company issued to the shareholders of BiomX Israel a total of 15,069,058 shares of the Company's Common Stock representing approximately 65% of the total shares issued and outstanding after giving effect to the Recapitalization Transaction. As a result of the Recapitalization Transaction, BiomX Israel became a wholly owned subsidiary of the Company. As the shareholders of BiomX Israel received the largest ownership interest in the Company, BiomX Israel was determined to be the "accounting acquirer" in the Recapitalization Transaction. As a result, the historical financial statements of the Company were replaced with the financial statements of BiomX Israel for all periods presented. Following the Recapitalization Transaction, the Company retained $60.1 million held in a trust account, after redemptions of a portion of shares of Common Stock issued in the initial public offering of the Company and held by certain shareholders. The numbers of shares and instruments convertible into shares included within these financial statements have been retroactively adjusted based on the equivalent number of shares received by the accounting acquirer in the Recapitalization Transaction. On October 28, 2019, the Company was renamed BiomX Inc. and the Company's shares of Common Stock, units, and warrants began trading in NYSE American under the symbols PHGE, PHGE.U, and PHGE.WS, respectively. On February 6, 2020, the Company's Common Stock also began trading on the Tel Aviv Stock Exchange. B. Risk factors: To date, the Company has not generated revenue from its operations. As of June 30, 2020, the Company had a cash and cash equivalent and restricted cash balance of approximately $60 million and short-term deposits of approximately $10 million, which management believes is sufficient to fund its operations for more than 12 months from the date of issuance of these condensed consolidated financial statements and sufficient to fund its operations necessary to continue development activities of its current proposed products. Consistent with its continuing R&D activities, the Company expects to continue to incur additional losses for the foreseeable future. The Company plans to continue to fund its current operations, as well as other development activities relating to additional product candidates, through future issuances of debt and/or equity securities and possibly additional grants from the Israel Innovation Authority ("IIA") or other government or non-for-profit institutions. The Company's ability to raise additional capital in the equity and debt markets is dependent on a number of factors including, but not limited to, the market demand for the Company's Common Stock, which itself is subject to a number of development and business risks and uncertainties, as well as the uncertainty that the Company would be able to raise such additional capital at a price or on terms that are favourable to us.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES C. Unaudited Condensed Financial Statements The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for condensed financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission ("SEC") regulations. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). The financial information contained in this report should be read in conjunction with the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019, that the Company filed with the SEC on March 26, 2020. D. Use of estimates in the preparation of financial statements The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities in the financial statements and the amounts of expenses during the reported years. Actual results could differ from those estimates. E. Reclassification Certain prior year amounts have been reclassified to conform to the current year presentation. F. Significant Accounting Policies The significant accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are identical to those applied in the preparation of the latest annual audited financial statements with the exception of the following: In August 2018, the FASB issued ASU No. 2018-13, "Changes to Disclosure Requirements for Fair Value Measurements," which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements and is effective for the Company beginning on January 1, 2020. This standard did not have a material impact on the Company's condensed consolidated financial statements and related disclosures. In November 2018, the FASB issued ASU No. 2018-18, "Collaborative Arrangements (Topic 808)," which clarifies the interaction between Topic 808 and Topic 606, "Revenue from Contracts with Customers". The Company adopted this standard in the first quarter of fiscal year 2020. This standard did not have a material impact on the Company's condensed consolidated financial statements and related disclosures. G. Recent Accounting Standards: In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-13, "Financial Instruments – Credit Losses", to improve information on credit losses for financial assets and net investment in leases that are not accounted for at fair value through net income. The ASU replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses. This guidance is effective for the Company beginning on January 1, 2023, with early adoption permitted. The Company does not expect that the adoption of this standard will have a significant impact on its consolidated financial statements and related disclosures. In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes" ("ASU 2019-12"), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for the Company beginning on January 1, 2021, with early adoption permitted. The Company does not expect that the adoption of this standard will have a significant impact on its consolidated financial statements and related disclosures.

Short-Term Deposits

Short-Term Deposits	6 Months Ended
	Jun. 30, 2020
Investments, All Other Investments [Abstract]
SHORT-TERM DEPOSITS	NOTE 3 – SHORT-TERM DEPOSITS Short-term deposits represent time deposits placed with banks with original maturities of greater than three months but less than one year. Interest earned is recorded as financial income in the consolidated statements of operations during the periods for which the Company held short-term deposits. As of June 30, 2020, the Company had deposits dominated in New Israeli Shekels ("NIS") and in USD at Leumi Bank (Israel) and BHI USA with fixed annual interest of 0.5% - 1.58% per year. As of June 30, 2019, the Company had deposits at Leumi Bank (Israel) and BHI USA with fixed annual interest of 2.4% - 3.6% per year.

Leases

Leases	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
LEASES	NOTE 4 – LEASES On January 1, 2019, the Company adopted ASU No. 2016-02, "Leases (Topic 842)" using the modified retrospective approach for all lease arrangements at the beginning period of adoption. The Company leases office space under operating leases. As of June 30, 2020, the Company's right-of-use assets and lease liabilities for operating leases totalled $979 thousand and $1,034 thousand, respectively. In May 2017, BiomX Israel entered into a lease agreement for office space in Ness Ziona, Israel for five years, beginning on June 1, 2017, with an option to extend for an additional five years. Monthly lease payments under the agreement are approximately $18 thousand. As part of the agreement, the Company has obtained a bank guarantee in favor of the property owner in the amount of approximately $95 thousand, representing four monthly lease and related payments. Lease expenses recorded in the condensed consolidated statements of operations were $56 thousand and $108 thousand for the three and six months ended June 30, 2020, respectively. Lease expenses recorded in the condensed consolidated statements of operations were $48 thousand and $96 thousand for the three and six months ended June 30, 2019, respectively. In September 2019, BiomX Israel entered into a lease agreement for office space in Ness Ziona, Israel for five years beginning on September 8, 2019, with an option to extend for an additional period until July 14, 2027. Monthly lease payments under the agreement are approximately $12 thousand. As part of the agreement, BiomX Israel obtained a bank guarantee in favor of the property owner in the amount of approximately $59 thousand, representing four monthly lease and related payments. Lease expenses recorded in the condensed consolidated statements of operations were $34 thousand and $70 thousand for the three and six months ended June 30, 2020, respectively. Supplemental cash flow information related to operating leases was as follows (USD in thousands): Three months ended Six months ended Cash payments for operating leases 90 178 As of June 30, 2020, the Company's operating leases had a weighted average remaining lease term of 3.75 years and a weighted average discount rate of 3%. Future lease payments under operating leases as of June 30, 2020 were as follows (USD in thousands): Operating Leases Remainder of 2020 $ 188 2021 $ 369 2022 $ 269 2023 $ 142 2024 $ 97 Total future lease payments $ 1,065 Less imputed interest (31 ) Total lease liability balance $ 1,034

Acquisition of Subsidiary

Acquisition of Subsidiary	6 Months Ended
	Jun. 30, 2020
Business Combinations [Abstract]
ACQUISITION OF SUBSIDIARY	NOTE 5 – ACQUISITION OF SUBSIDIARY In November 2017, BiomX Israel signed a share purchase agreement with the shareholders of RondinX Ltd. In accordance with the share purchase agreement, BiomX Israel acquired 100% control and ownership of RondinX Ltd. for consideration valued at $4.5 million. The consideration included the issuance of 250,023 Preferred A Shares, the issuance of warrants to purchase an aggregate of 4,380 Series A-1 preferred shares and additional contingent consideration. The contingent consideration is based on the attainment of future clinical, developmental, regulatory, commercial and strategic milestones relating to product candidates for the treatment of primary sclerosing cholangitis or entry into qualifying collaboration agreements with certain third parties. The contingent consideration may require the Company to issue 567,729 shares of Common Stock upon the attainment of certain milestones, as well as make future cash payments and/or issue additional shares of the most senior class of the Company's shares authorized or outstanding as of the time the payment is due, or a combination of both of up to $32 million within ten years from the closing of the share purchase agreement. The contingent consideration may also require the Company to pay a qualifying up-front fee upon entering of agreements with certain third parties or their affiliates that include within three years from the closing of the share purchase agreement. The Company has the discretion of determining whether milestone payments will be made in cash or by issuance of shares. The contingent consideration is accounted for at fair value (level 3). There were no changes in the fair value hierarchy leveling during the six months ended June 30, 2020 or 2019. The change in the fair value of the contingent consideration as of June 30, 2020 and June 30, 2019 was as follows (USD in thousands): Contingent consideration As of December 31, 2019 585 Revaluation of contingent consideration 58 As of June 30, 2020 643 Contingent consideration As of December 31, 2018 889 Revaluation of contingent consideration 14 As of June 30, 2019 903

In-Process Research and Develop

In-Process Research and Development	6 Months Ended
	Jun. 30, 2020
In Process Research And Development [Abstract]
IN-PROCESS RESEARCH AND DEVELOPMENT	NOTE 6 – IN-PROCESS RESEARCH AND DEVELOPMENT Intangible assets acquired in the RondinX Ltd. acquisition (see Note 5) were determined to be in-process R&D. In accordance with ASC 350-30-35-17A ("Intangible assets with indefinite lives"), R&D assets acquired in a business combination are considered an indefinite-lived intangible asset until completion or abandonment of the associated R&D efforts. On January 1, 2020, the in-process R&D efforts were completed. The Company had determined the useful life of the R&D assets for three years and began amortizing these assets accordingly in the financial statements. Amortization expenses recorded in the condensed consolidated statements of operations were $379 thousand and $758 thousand for the three and six months ended June 30, 2020, respectively. Based on management's analysis, there was no impairment for the three and six months ended June 30, 2020 or 2019.

Commitments and Contingent Liab

Commitments and Contingent Liabilities	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	NOTE 7 – COMMITMENTS AND CONTINGENT LIABILITIES A. During 2015, 2016 and 2017, BiomX Israel submitted three applications to the IIA for an R&D project for the technological incubators program. The approved budget per year per application was NIS 2.7 million (approximately $726 thousand). According to the IIA directives, the IIA transferred to the Company 85% of the approved budget while the remainder of the budget was funded by certain shareholders. In December 2019, the IIA approved a new application for a total budget of NIS 10.8 million (approximately $3.1 million). IIA committed to funding 30% of the approved budget. The program is for the period beginning July 2019 through December 2019. BiomX Israel has not yet submitted the final report to the IIA for this program. During December 2019, BiomX Israel submitted three additional applications to the IIA, for a total budget of NIS 41.1 million (approximately $11.9 million). The IIA approved one, for a total budget of NIS 15.6 million (approximately $4.4 million). The IIA will fund 30% of this budget. The program is for the period beginning January 2020 through December 2020. As of June 30, 2020, the Company received NIS 1.6 million (approximately $0.5 million) from the IIA with respect to the program. According to the agreement with the IIA, BiomX Israel will pay royalties of 3% to 3.5% of future sales up to an amount equal to the accumulated grant received, including annual interest of LIBOR linked to the USD. BiomX Israel may be required to pay additional royalties upon the occurrence of certain events as determined by the IIA, that are within the control of the Company. No such events have occurred or were probable of occurrence as of the balance sheet date with respect to these royalties. Repayment of the grant is contingent upon the successful completion of the Company's R&D programs and generating sales. The Company has no obligation to repay these grants if the R&D program fails, is unsuccessful or aborted or if no sales are generated. The Company had not yet generated sales as of June 30, 2020; therefore, no liability was recorded in these condensed consolidated financial statements. As of June 30, 2020, the Company had a contingent obligation to the IIA in the amount of approximately $2.3 million including annual interest of LIBOR linked to the USD. B. In June 2015, BiomX Israel entered into a Research and License Agreement (the "2015 License Agreement") as amended with Yeda Research and Development Company Limited ("Yeda"), according to which Yeda undertakes to procure the performance of certain research, including proof-of-concept studies testing in-vivo phage eradication against a model bacteria in germ free mice, development of an inflammatory bowel disease ("IBD") model in animals under germ-free conditions and establishing an in-vivo method for measuring immune induction capability (Th1) of bacteria, followed by testing several candidate IBD inducing bacterial strains during the research period, as defined in the 2015 License Agreement and subject to the terms and conditions specified in the 2015 License Agreement. BiomX Israel contributed an aggregate of approximately $1.8 million to the research budget agreed upon in the 2015 License Agreement. In addition, Yeda granted BiomX Israel an exclusive worldwide license for the development, production and sale of the products, as defined and subject to the terms and conditions specified in the 2015 License Agreement. In return, BiomX Israel will pay Yeda annual license fees of approximately $10 thousand and royalties on revenues as defined in the 2015 License Agreement. In addition, in the event of certain mergers and acquisitions by the Company, Yeda will be entitled to an amount equivalent to 1% of the consideration received under such transaction (the "Exit Fee"), as adjusted per the terms of the 2015 License agreement. Upon the closing of the Recapitalization Transaction, the provisions of the 2015 License agreement related to the Exit Fee were amended wherein the Company will be obligated to pay Yeda a one-time payment instead of the Exit Fee, as described in the amendment which will not exceed 1% of the consideration received under any merger or acquisition involving the Company (see note 7H). As the Company has not yet generated revenue from operations, no provision was included in the condensed consolidated financial statements as of June 30, 2020 and December 31, 2019 with respect to the 2015 License Agreement. C In May 2017, BiomX Israel signed an additional agreement with Yeda (the "2017 License Agreement"), according to which, Yeda provided a license to the Company. As consideration for the license, the Company will pay $10 thousand over the term of the 2017 License Agreement, unless earlier terminated by either party, and granted Yeda 591,382 warrants to purchase shares of Common Stock of the BiomX Inc. Refer to Note 8 below for the terms of the warrants granted. In addition, the 2017 License Agreement includes additional consideration contingent upon future sales or sublicensing revenue. As the Company has not yet generated revenue from operations, no provision was included in the consolidated financial statements with respect to the 2017 License Agreement as of June 30, 2020 and December 31, 2019. In July 2019, the Company and Yeda amended the 2015 License Agreement and the 2017 License Agreement with Yeda (the "Amendment"). See note 7H regarding the amendment. D In April 2017, BiomX Israel signed an exclusive patent license agreement with the Massachusetts Institute of Technology ("MIT") covering methods to synthetically engineer phage. According to the agreement, BiomX Israel received an exclusive, royalty-bearing license to certain patents held by MIT. In return, BiomX Israel paid an initial license fee of $25 thousand during the year ended December 31, 2017 and is required to pay certain license maintenance fees of up to $250 thousand in each subsequent year and following the commercial sale of licensed products. BiomX Israel is also required to make payments to MIT upon the satisfaction of development and commercialization milestones totaling up to $2.4 million in aggregate as well as royalty payments on future revenues. The consolidated financial statements as of June 30, 2020 and December 31, 2019 include a liability with respect to this agreement in the amount of $156 thousand and $108 thousand, respectively. E. As successor in interest to RondinX Ltd., BiomX Israel is a party to a license agreement dated March 20, 2016 with Yeda, pursuant to which BiomX Israel has a worldwide exclusive license to Yeda's know-how, information and patents related to the Company's meta-genomics target discovery platform. As consideration for the license, BiomX Israel will pay license fees of $10 thousand subject to the terms and conditions of the agreement. Either party has the option to terminate the agreement at any time by way of notice to the other party as outlined in the agreement. In addition, the Company will pay a royalty in the low single digits on revenue of products. The consolidated financial statements as of June 30, 2020 and December 31, 2019 include a liability with respect to this agreement in the amount of $89 thousand and $260 thousand, respectively. F. In December 2017, BiomX Israel signed a patent license agreement with Keio University and JSR Corporation in Japan. According to the agreement, BiomX Israel received an exclusive patent license to certain patent rights related to the Company's IBD program. In return, the Company will pay annual license fee of between $15 thousand to $25 thousand subject to the terms and conditions specified in the agreement. Additionally, the Company is obligated to make additional payments based upon the achievement of clinical and regulatory milestones up to an aggregate of $3.2 million and royalty payments based on future revenue. As the Company has not yet generated revenue from operations, and the achievement of certain milestones is not probable, no provision was included in the condensed consolidated financial statements as of June 30, 2020 and December 31, 2019 with respect to the agreement. In April 2019, BiomX Israel signed an additional patent license agreement with Keio University and JSR Corporation in Japan. According to the agreement, BiomX Israel received an exclusive sublicense by JSR to certain patent rights related to the Company's Primary Sclerosing Cholangitis program. In return, the Company is required (i) to pay a license issue fee of $20 thousand and annual license fees ranging from $15 thousand to $25 thousand and (ii) make additional payments based upon the achievement of clinical and regulatory milestones up to an aggregate of $3.2 million and (iii) make tiered royalty payments, in the low single digits based on future revenue. The consolidated financial statements include liabilities with respect to this agreement in the amount of $398 thousand and $217 thousand as of June 30, 2020 and December 31, 2019, respectively. G. BiomX Israel committed to enter into loan agreements with certain shareholders who were subject to taxation in Israel in connection with the Recapitalization Transaction. The loans are for a period of up to two years, are non-recourse, and are secured by Company shares issued to them that have a value that equals three times the loan amount. If any of such shareholders defaults on such loan, the Company will have the right to forfeit or sell such number of shares as have a value equal to the amount of the loan (plus interest accrued thereon) not timely repaid, based on their market price at the time of such forfeiture or sale. As of June 30, 2020, one loan was granted in the amount of $19 thousand, and the aggregate amount of the remaining potential commitment is $89 thousand. All other shareholders waived their right to the loans. The number of shares of Common Stocks in respect of which the $19 thousand loan was granted was 5,700. The granting of the loan and the restrictions imposed on the related Common Stock until repayment of the loan were accounted as an acquisition of treasury stock by the Company at an amount equal to the loan. H. In July 2019, the Company and Yeda amended the 2015 License Agreement and to the 2017 License Agreement with Yeda. Pursuant to the Amendment, following the closing of the Recapitalization Transaction, the provisions of the Yeda license agreements related to the exit fee were amended so that the Company is obligated to pay Yeda a one-time payment as described in the Amendment which will not exceed 1% of the consideration received in the event of any merger or acquisition involving the Company instead of the Exit Fee, with respect to each license agreement.

Shareholders Equity

Shareholders Equity	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
SHAREHOLDERS EQUITY	NOTE 8 – SHAREHOLDERS EQUITY A. Share Capital: Common Stock: The Company is authorized to issue 60,000,000 shares of Common Stock. Holders of the Company's Common Stock are entitled to one vote for each share. As of June 30, 2020, the Company had 23,145,964 issued shares and 23,140,264 outstanding shares of Common Stock. Share Exchange: As detailed in Note 1, as part of the Recapitalization Transaction on October 28, 2019, the Company issued 15,069,058 shares of Common Stock in exchange for approximately 65% of the issued and outstanding ordinary shares and all the preferred shares of BiomX Israel. The number of shares prior to the Recapitalization Transaction have been retroactively adjusted based on the equivalent numbers of shares received by the accounting acquirer in the Recapitalization Transaction. In addition, the Company also agreed to issue the following number of additional shares of Common Stock, in the aggregate, to Chardan Healthcare Acquisition Corp. shareholders on a pro rata basis, subject to the Company's achievement of the conditions specified below following the Recapitalization Transaction (all with respect to the Company's shares of Common Stock traded on NYSE American): A. 2,000,000 additional shares of the Company's Common Stock if the daily volume weighted average price of the Company's Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2022 is greater than or equal to $16.50 per share. B. 2,000,000 additional shares of the Company's Common Stock if the daily volume weighted average price of the Company's Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2024 is greater than or equal to $22.75 per share. C. 2,000,000 additional shares of the Company's Common Stock if the daily volume weighted average price of the Company's Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2026 is greater than or equal to $29.00 per share. Preferred Stock: The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 per share with such designation, rights and preferences as may be determined from time to time by the Company's Board of Directors. B. Share-based compensation: In 2015, the Board of Directors of BiomX Israel approved a plan for the allocation of options to employees, service providers, and officers (the "2015 Plan"). The options represented a right to purchase one ordinary share of BiomX Israel in consideration of the payment of an exercise price. Also, the options were granted in accordance with the "capital gains route" under section 102 and section 3(i) of the Israeli Income Tax Ordinance and section 409A of the Israeli Internal Revenue Code. The original 2015 Plan was adjusted following the Recapitalization Transaction on October 28, 2019 such that each outstanding option entitles its holder to purchase one share of Common Stock of the Company. As a result, the number of options and exercise price per share were adjusted in a technical manner such that there was no change in the fair value of the awards under the adjusted 2015 Plan. The number of outstanding options and exercise prices in this Note have been restated to reflect the adjusted 2015 Plan. As of June 30, 2020, there are no shares remaining for issuance under the 2015 Plan. During 2019, the Board approved the grant of 704,669 options without consideration to 22 employees and 79,630 options without consideration to two consultants. 527,716 of the options granted are to the executive officers of the Company. These options were granted under the 2015 Plan. During 2019, 74,581 options were exercised to purchase shares of Common Stock at an average exercise price of $1.34 per share. Certain senior employees are entitled to full acceleration of their unvested options upon the occurrence of a cumulative two certain events. In 2019, the Company adopted a new incentive plan (the "2019 Plan") to grant 1,000 options, exercisable for Common Stock. The aggregate number of shares of Common Stock that may be delivered pursuant to the 2019 Plan will automatically increase on January 1 of each year, commencing on January 1, 2020 and ending on (and including) January 1, 2029, in an amount equal to four percent (4%) of the total number of shares of Common Stock outstanding on December 31 of the preceding calendar year. Notwithstanding the foregoing, the Board of Directors may act prior to January 1 of a given year to provide that there will be no January 1 increase for such year or that the increase for such year will be a lesser number of Common Stock than provided herein. On January 1, 2020, number of shares of Common Stock available to grant was increased by 914,741. On March 25, 2020, the Board of Directors approved the grant of 814,700 options without consideration to 65 employees, one consultant, four senior officers (one of whom is a consultant), and six directors under the 2019 Plan. These options were granted at an exercise price of $6.21 per share with vesting periods ranging from three to four years. Directors and senior officers are entitled to full acceleration of their unvested options upon the occurrence of cumulative two certain events. On May 5, 2020, the Board of Directors approved the grant of 79,000 options without consideration to four employees, under the 2019 Plan. These options were granted at an exercise price of $5.59 per share with a vesting period of four years. As of June 30, 2020, there are 28,041 shares available for issuance under the 2019 Plan. The fair value of each option was estimated as of the date of grant or reporting period using the Black-Scholes option-pricing model, using the following assumptions: Six months ended June 30, 2020 2019 Underlying value of share of Common Stock ($) 5.59-6.21 4.91 Exercise price ($) 5.59-6.21 4.91 Expected volatility (%) 85.0 93.1 Term of the option (years) 6.25 6.25 Risk-free interest rate (%) 0.37-0.52 2.23 The cost of the benefit embodied in the options granted during the six months ended June 30, 2020, based on their fair value as at the grant date, is estimated to be $3.9 million. These amounts will be recognized in the consolidated statements of operations over the vesting period. (1) A summary of options granted to purchase the Company's Common Stock under the Company's share option plans is as follows: For the six months ended June 30, 2020 Number of Options Weighted average exercise price Aggregate intrinsic value USD USD in thousands Outstanding at the beginning of period 3,143,802 1.09 25,733 Granted 893,700 6.16 Forfeited (41,925 ) 2.45 Exercised (277,429 ) 0.63 Outstanding at the end of period 3,718,148 3.08 10,484 Vested at end of period 1,641,346 Weighted average remaining contractual life – years as of June 30, 2020 6.92 Warrants: As of June 30, 2020, and December 31, 2019, the Company had the following outstanding warrants to purchase Common Stock as follows: Warrant Issuance Date Expiration Date Exercise Price Number of Private Warrants issued to Yeda (see 1 below) May 11, 2017 May 11, 2025 (* ) 591,382 Private Warrants issued to founders (see 2 below) November 27, 2017 - 10,589 Private Placement Warrants (see 3 below) IPO (December 13, 2018) December 13, 2023 11.50 2,900,000 Public Warrants (see 4 below) IPO (December 13, 2018) October 28, 2024 11.50 3,500,000 7,001,971 (*) less than $0.001. 1. In May 2017, in accordance with the 2017 License Agreement (see also Note 7C), BiomX Israel issued to Yeda, for nominal consideration, 591,382 warrants to purchase Common Stock at $0.0001 nominal value. No expenses or income were recorded in R&D expenses, net in the consolidated statements of comprehensive loss for the six months ended June 30, 2020 and 2019. 236,552 warrants were fully vested and exercisable on the date of their issuance. The remainder of the warrants will vest and become exercisable subject to achievement of certain milestones specified in the agreement as follows: a. 177,414 upon the filing of a patent application covering any Discovered Target or a Product (both as defined in the 2017 License Agreement). b. 118,277 upon achievement of the earlier of the following milestones by the Company: (i) execution of an agreement with a pharmaceutical company with respect to the commercialization of any of the Company's licensed technology or the Consulting IP or a Product (both defined in the 2017 License Agreement) or (ii) the filing of a patent application covering any Discovered Target (as defined in the 2017 License Agreement) or a Product. c. 59,139 upon completion of a Phase 1 clinical trial in respect of a Product (as defined in the 2017 License Agreement). 2. In November 2017, BiomX Israel issued 7,615 warrants to Yeda and 2,974 warrants to its founders. All the warrants were fully vested at their grant date and will expire immediately prior to a consummation of an M&A transaction. The warrants did not expire as a result of the Recapitalization Transaction and have no exercise price. 3. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Company initial public offering, except that the Private Placement Warrants are exercisable for cash (even if a registration statement covering the shares of Common Stock issuable upon exercise of such warrants is not effective) or on a cashless basis, at the holder's option, and will not be redeemable by the Company, in each case, so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants. 4. The Public Warrants became exercisable upon the closing of the Recapitalization Transaction. No fractional shares will be issued upon exercise of the Public Warrants. Therefore, Public Warrants must be exercised in multiples of two warrants. The Company filed a Registration Statement on Form S-1 for the resale of shares underlying the warrants on December 13, 2019, which was declared effective on January 3, 2020. The Public Warrants will expire five years after the completion of the Recapitalization Transaction or earlier upon redemption or liquidation. The Company may redeem the Public Warrants: ● in whole and not in part; ● at a price of $0.01 per warrant; ● at any time during the exercise period; ● upon a minimum of 30 days' prior written notice of redemption; ● if, and only if, the last sale price of the Company's Common Stock equals or exceeds $16.00 per share for any 20 trading days within a 30-trading day period ending on the third business day prior to the date on which the Company sends the notice of redemption to the warrant holders; and ● if, and only if, there is a current registration statement in effect with respect to the shares of Common Stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption. If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a "cashless basis," as described in the warrant agreement. The exercise price and number of shares of Common Stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of Common Stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. (2) The following table sets forth the total share-based payment expenses resulting from options granted, included in the consolidated statements of operations (USD in thousands): Six months ended June 30, 2020 2019 Research and development expenses, net 502 367 General and administrative 512 264 1,014 631 Three months ended June 30, 2020 2019 Research and development expenses, net 310 173 General and administrative 367 154 677 327

Related Parties

Related Parties	6 Months Ended
	Jun. 30, 2020
Related Party Transactions [Abstract]
RELATED PARTIES	NOTE 9 – RELATED PARTIES On October 31, 2018, BiomX Israel entered into a research collaboration agreement with Janssen Research & Development, LLC ("Janssen"), an affiliate of shareholder Johnson & Johnson Development Corporation, for a collaboration on biomarker discovery for IBD. Under the agreement, BiomX Israel was eligible to receive fees totaling $167 thousand in installments of $50 thousand within 60 days of signing of the agreement, $17 thousand upon completion of data processing, and two installments of $50 thousand each, upon delivery of Signature Phase I of the Final Study Report (both terms defined within the agreement). Unless terminated earlier, this agreement was in effect, until 30 days after the parties complete the research program and BiomX Israel provide Janssen with a final study report. The research period started during March 2019 and ended in September 2019. The final report was provided to Janssen in December 2019.

Basic Loss Per Share

Basic Loss Per Share	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
BASIC LOSS PER SHARE	NOTE 10 – BASIC LOSS PER SHARE The basic and diluted net loss per share and weighted average number of shares of Common Stock used in the calculation of basic and diluted net loss per share are as follows (USD in thousands, except share and per share data): Six months ended June 30, 2020 2019 Net loss 12,107 7,003 Interest accrued on preferred shares (pre-merger – BiomX Israel) - 2,381 Net loss used in the calculation of basic net loss per share 12,107 9,384 Net loss per share 0.53 4.68 Weighted average number of shares of Common Stock 22,944,482 2,005,047 Three months ended June 30, 2020 2019 Net loss 6,206 3,778 Interest accrued on preferred shares (pre-merger – BiomX Israel) - 1,231 Net loss used in the calculation of basic net loss per share 6,206 5,009 Net loss per share 0.27 2.50 Weighted average number of shares of Common Stock 22,944,482 2,005,047

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Unaudited Condensed Financial Statements	C. Unaudited Condensed Financial Statements The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for condensed financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission ("SEC") regulations. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). The financial information contained in this report should be read in conjunction with the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019, that the Company filed with the SEC on March 26, 2020.
Use of estimates in the preparation of financial statements	D. Use of estimates in the preparation of financial statements The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities in the financial statements and the amounts of expenses during the reported years. Actual results could differ from those estimates.
Reclassification	E. Reclassification Certain prior year amounts have been reclassified to conform to the current year presentation.
Significant Accounting Policies	F. Significant Accounting Policies The significant accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are identical to those applied in the preparation of the latest annual audited financial statements with the exception of the following: In August 2018, the FASB issued ASU No. 2018-13, "Changes to Disclosure Requirements for Fair Value Measurements," which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements and is effective for the Company beginning on January 1, 2020. This standard did not have a material impact on the Company's condensed consolidated financial statements and related disclosures. In November 2018, the FASB issued ASU No. 2018-18, "Collaborative Arrangements (Topic 808)," which clarifies the interaction between Topic 808 and Topic 606, "Revenue from Contracts with Customers". The Company adopted this standard in the first quarter of fiscal year 2020. This standard did not have a material impact on the Company's condensed consolidated financial statements and related disclosures.
Recent Accounting Standards	G. Recent Accounting Standards: In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-13, "Financial Instruments – Credit Losses", to improve information on credit losses for financial assets and net investment in leases that are not accounted for at fair value through net income. The ASU replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses. This guidance is effective for the Company beginning on January 1, 2023, with early adoption permitted. The Company does not expect that the adoption of this standard will have a significant impact on its consolidated financial statements and related disclosures. In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes" ("ASU 2019-12"), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for the Company beginning on January 1, 2021, with early adoption permitted. The Company does not expect that the adoption of this standard will have a significant impact on its consolidated financial statements and related disclosures.

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Schedule of supplemental cash flow information related to operating leases	Three months ended Six months ended Cash payments for operating leases 90 178
Schedule of future lease payments under operating leases	Operating Leases Remainder of 2020 $ 188 2021 $ 369 2022 $ 269 2023 $ 142 2024 $ 97 Total future lease payments $ 1,065 Less imputed interest (31 ) Total lease liability balance $ 1,034

Acquisition of Subsidiary (Tabl

Acquisition of Subsidiary (Tables)	6 Months Ended
	Jun. 30, 2020
Business Combinations [Abstract]
Schedule of change in the fair value of the contingent consideration	Contingent consideration As of December 31, 2019 585 Revaluation of contingent consideration 58 As of June 30, 2020 643 Contingent consideration As of December 31, 2018 889 Revaluation of contingent consideration 14 As of June 30, 2019 903

Shareholders Equity (Tables)

Shareholders Equity (Tables)	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Schedule of black-scholes option-pricing model	Six months ended June 30, 2020 2019 Underlying value of share of Common Stock ($) 5.59-6.21 4.91 Exercise price ($) 5.59-6.21 4.91 Expected volatility (%) 85.0 93.1 Term of the option (years) 6.25 6.25 Risk-free interest rate (%) 0.37-0.52 2.23
Schedule of options granted to purchase ordinary shares	For the six months ended June 30, 2020 Number of Options Weighted average exercise price Aggregate intrinsic value USD USD in thousands Outstanding at the beginning of period 3,143,802 1.09 25,733 Granted 893,700 6.16 Forfeited (41,925 ) 2.45 Exercised (277,429 ) 0.63 Outstanding at the end of period 3,718,148 3.08 10,484 Vested at end of period 1,641,346 Weighted average remaining contractual life – years as of June 30, 2020 6.92
Schedule of outstanding warrants	Warrant Issuance Date Expiration Date Exercise Price Number of Private Warrants issued to Yeda (see 1 below) May 11, 2017 May 11, 2025 (* ) 591,382 Private Warrants issued to founders (see 2 below) November 27, 2017 - 10,589 Private Placement Warrants (see 3 below) IPO (December 13, 2018) December 13, 2023 11.50 2,900,000 Public Warrants (see 4 below) IPO (December 13, 2018) October 28, 2024 11.50 3,500,000 7,001,971 (*) less than $0.001.
Schedule of share-based payment expenses	Six months ended June 30, 2020 2019 Research and development expenses, net 502 367 General and administrative 512 264 1,014 631 Three months ended June 30, 2020 2019 Research and development expenses, net 310 173 General and administrative 367 154 677 327

Basic Loss Per Share (Tables)

Basic Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Schedule of calculation of basic and diluted net loss per share	Six months ended June 30, 2020 2019 Net loss 12,107 7,003 Interest accrued on preferred shares (pre-merger – BiomX Israel) - 2,381 Net loss used in the calculation of basic net loss per share 12,107 9,384 Net loss per share 0.53 4.68 Weighted average number of shares of Common Stock 22,944,482 2,005,047 Three months ended June 30, 2020 2019 Net loss 6,206 3,778 Interest accrued on preferred shares (pre-merger – BiomX Israel) - 1,231 Net loss used in the calculation of basic net loss per share 6,206 5,009 Net loss per share 0.27 2.50 Weighted average number of shares of Common Stock 22,944,482 2,005,047

General (Details)

General (Details) - USD ($) $ in Thousands	1 Months Ended	6 Months Ended
	Oct. 28, 2019	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
General (Textual)
Recapitalization transaction, percentage	100.00%
Issued of common stock		23,145,964	22,862,835
Total consideration from merger		$ 60,100
Restricted cash and cash equivalent		60,230	$ 72,410	$ 16,237	$ 8,693
Short-term deposits		$ 10,390	$ 10,003
Risk factors, description		Operations for more than 12 months from the date of issuance of these condensed consolidated financial statements and sufficient to fund its operations necessary to continue development activities of its current proposed products.
BiomX Israel [Member]
General (Textual)
Issued of common stock	15,069,058
Percentage issued to former shareholders of subsidiary in the merger	65.00%

Short-Term Deposits (Details)

Short-Term Deposits (Details)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Short-Term Deposits (Textual)
Short-term deposits, description	Short-term deposits represent time deposits placed with banks with original maturities of greater than three months but less than one year.
Minimum [Member]
Short-Term Deposits (Textual)
Fixed annual interest bearing, percentage	0.50%	2.40%
Maximum [Member]
Short-Term Deposits (Textual)
Fixed annual interest bearing, percentage	1.58%	3.60%

Leases (Details)

Leases (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020
Leases [Abstract]
Cash payments for operating leases	$ 90	$ 178

Leases (Details 1)

Leases (Details 1) $ in Thousands	Jun. 30, 2020USD ($)
Leases [Abstract]
Remainder of 2020	$ 188
2021	369
2022	269
2023	142
2024	97
Total future lease payments	1,065
Less imputed interest	(31)
Total lease liability balance	$ 1,034

Leases (Details Textual)

Leases (Details Textual) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020	Dec. 31, 2019
Leases (Textual)
Leases expense for one contract	$ 48	$ 96
Weighted average remaining lease term	3 years 9 months	3 years 9 months
Weighted average discount rate	3.00%	3.00%
Operating lease right-of-use asset	$ 979	$ 979	$ 1,148
Total lease liability balance	1,034	$ 1,034
Lease Agreement [Member]
Leases (Textual)
Operating lease, description		The agreement is for five years, beginning on June 1, 2017, with an option to extend for an additional five years.
Monthly lease payments		$ 18
Leases expense for one contract	56	108
Bank guarantee to property amount		$ 95
Lease Agreements One [Member]
Leases (Textual)
Operating lease, description		The agreement is for five years beginning on September 8, 2019, with an option to extend for an additional period until July 14, 2027.
Monthly lease payments		$ 12
Leases expense for one contract	$ 34	70
Bank guarantee to property amount		$ 58

Acquisition of Subsidiary (Deta

Acquisition of Subsidiary (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Contingent consideration
Opening balance	$ 585	$ 889
Revaluation of contingent consideration	58	14
Ending balance	$ 643	$ 903

Acquisition of Subsidiary (De_2

Acquisition of Subsidiary (Details Textual)	1 Months Ended
	Nov. 30, 2017
BiomX Israel [Member]
Acquisition of Subsidiary (Textual)
Share purchase agreement, description	BiomX Israel signed a share purchase agreement with the shareholders of RondinX Ltd. In accordance with the share purchase agreement, BiomX Israel acquired 100% control and ownership of RondinX Ltd. for consideration valued at $4.5 million. The consideration included the issuance of 250,023 Preferred A Shares, the issuance of warrants to purchase an aggregate of 4,380 Series A-1 preferred shares and additional contingent consideration. The contingent consideration is based on the attainment of future clinical, developmental, regulatory, commercial and strategic milestones relating to product candidates for the treatment of primary sclerosing cholangitis or entry into qualifying collaboration agreements with certain third parties. The contingent consideration may require the Company to issue 567,729 shares of Common Stock upon the attainment of certain milestones, as well as make future cash payments and/or issue additional shares of the most senior class of the Company's shares authorized or outstanding as of the time the payment is due, or a combination of both of up to $32 million within ten years from the closing of the share purchase agreement. The contingent consideration may also require the Company to pay a qualifying up-front fee upon entering of agreements with certain third parties or their affiliates that include within three years from the closing of the share purchase agreement.

In-Process Research and Devel_2

In-Process Research and Development (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020
In-Process Research and Development (Textual)
Amortization expenses	$ 379	$ 758
Useful life for intangible asset		3 years

Commitments and Contingent Li_2

Commitments and Contingent Liabilities (Details) ₪ in Thousands, $ in Thousands

1 Months Ended

6 Months Ended

12 Months Ended

Apr. 30, 2019

Dec. 31, 2017USD ($)

Dec. 31, 2017ILS (₪)

May 31, 2017USD ($)

Jun. 30, 2015USD ($)

Jun. 30, 2020USD ($)shares

Jun. 30, 2020ILS (₪)shares

Dec. 31, 2019USD ($)

Dec. 31, 2019ILS (₪)

Dec. 31, 2017USD ($)

Jun. 30, 2019USD ($)

Dec. 31, 2018USD ($)

Commitments and Contingent Liabilities (Textual)

Approved budget

$ 726

Percentage of approved budget

85.00%

85.00%

30.00%

30.00%

Contingent obligation

$ 643

$ 585

$ 903

$ 889

New application of total budget amount

$ 3,100

Other commitments, description

The program is for the period beginning January 2020 through December 2020.

The program is for the period beginning January 2020 through December 2020.

The program is for the period beginning July 2019 through December 2019.

The program is for the period beginning July 2019 through December 2019.

Additional budget

$ 11,900

Amount of liabilities recorded to agreement

$ 398

217

License Agreement [Member]

Commitments and Contingent Liabilities (Textual)

Approved budget

$ 1,800

Annual license fees

$ 10

NIS [Member]

Commitments and Contingent Liabilities (Textual)

Approved budget | ₪

₪ 2,700

New application of total budget amount | ₪

₪ 10,800

Additional budget | ₪

41,100

2017 License Agreement [Member]

Commitments and Contingent Liabilities (Textual)

Consideration percentage

1.00%

Annual license fees

$ 10

10

Additional Application [Member]

Commitments and Contingent Liabilities (Textual)

Additional budget

$ 500

4,400

Commitments and Contingent Liabilities, description

(i) to pay a license issue fee of $20 thousand and annual license fees ranging from $15 thousand to $25 thousand and (ii) make additional payments based upon the achievement of clinical and regulatory milestones up to an aggregate of $3.2 million and (iii) make tiered royalty payments, in the low single digits based on future revenue.

The Company will pay annual license fee of between $15 thousand to $25 thousand subject to the terms and conditions specified in the agreement. Additionally, the Company is obligated to make additional payments based upon the achievement of clinical and regulatory milestones up to an aggregate of $3.2 million and royalty payments based on future revenue.

Additional Application [Member] | NIS [Member]

Commitments and Contingent Liabilities (Textual)

Additional budget | ₪

₪ 1,600

₪ 15,600

2015 License Agreement [Member]

Commitments and Contingent Liabilities (Textual)

Consideration percentage

1.00%

Maximum [Member]

Commitments and Contingent Liabilities (Textual)

Royalties rate

3.00%

3.00%

Annual license fees

$ 15

Minimum [Member]

Commitments and Contingent Liabilities (Textual)

Royalties rate

3.50%

3.50%

Annual license fees

$ 25

Loan Agreements [Member]

Commitments and Contingent Liabilities (Textual)

Outstanding balance of the loan

$ 19

Aggregate amount of the remaining potential commitment

$ 89

260

Number of common stocks granted | shares

5,700

5,700

Patent License Agreement [Member]

Commitments and Contingent Liabilities (Textual)

Other commitments, description

BiomX Israel is also required to make payments to MIT upon the satisfaction of development and commercialization milestones totaling up to $2.4 million in aggregate as well as royalty payments on future revenues.

BiomX Israel is also required to make payments to MIT upon the satisfaction of development and commercialization milestones totaling up to $2.4 million in aggregate as well as royalty payments on future revenues.

Annual license fees

$ 25

Maximum payments of license maintenance fees

$ 250

Amount of liabilities recorded to agreement

$ 156

$ 108

Party to a license agreement [Member]

Commitments and Contingent Liabilities (Textual)

Other commitments, description

The consolidated financial statements as of June 30, 2020 and December 31, 2019 include a liability with respect to this agreement in the amount of $89 thousand and $260 thousand, respectively.

The consolidated financial statements as of June 30, 2020 and December 31, 2019 include a liability with respect to this agreement in the amount of $89 thousand and $260 thousand, respectively.

Shareholders Equity (Details)

Shareholders Equity (Details) - $ / shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Underlying value of share of Common Stock ($)		4.91
Exercise price ($)		$ 4.91
Expected volatility (%)	85.00%	93.10%
Term of the option (years)	6 years 2 months 30 days	6 years 2 months 30 days
Risk-free interest rate (%)		2.23%
Minimum [Member]
Underlying value of share of Common Stock ($)	5.59
Exercise price ($)	$ 5.59
Risk-free interest rate (%)	0.37%
Maximum [Member]
Underlying value of share of Common Stock ($)	6.21
Exercise price ($)	$ 6.21
Risk-free interest rate (%)	0.52%

Shareholders Equity (Details 1)

Shareholders Equity (Details 1) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2020
Number of Options
Outstanding, beginning balance	3,143,802
Granted	893,700
Forfeited	(41,925)
Exercised	(277,429)
Outstanding, ending balance	3,718,148
Vested at end of period	1,641,346
Weighted average remaining contractual life - years	6 years 11 months 1 day
Weighted average exercise price
Outstanding, beginning balance	$ 1.09
Granted	6.16
Forfeited	2.45
Exercised	0.63
Outstanding, ending balance	$ 3.08
Aggregate intrinsic value
Outstanding, beginning balance	$ 25,733
Outstanding, ending balance	$ 10,484

Shareholders Equity (Details 2)

Shareholders Equity (Details 2)	6 Months Ended
	Jun. 30, 2020$ / sharesshares
Number of Shares of Common Stock Underlying Warrants	7,001,971
Private Warrants issued to Yeda [Member]
Issuance Date	May 11, 2017
Expiration Date	May 11, 2025
Exercise Price Per Share | $ / shares		[1]
Number of Shares of Common Stock Underlying Warrants	591,382
Private Warrants issued to founders [Member]
Issuance Date	Nov. 27, 2017
Exercise Price Per Share | $ / shares
Number of Shares of Common Stock Underlying Warrants	10,589
Private Placement Warrants [Member] | IPO [Member]
Issuance Date	Dec. 13, 2018
Expiration Date	Dec. 13, 2023
Exercise Price Per Share | $ / shares	$ 11.50
Number of Shares of Common Stock Underlying Warrants	2,900,000
Public Warrants [Member] | IPO [Member]
Issuance Date	Dec. 13, 2018
Expiration Date	Oct. 28, 2024
Exercise Price Per Share | $ / shares	$ 11.50
Number of Shares of Common Stock Underlying Warrants	3,500,000
[1]	less than $0.001.

Shareholders Equity (Details 3)

Shareholders Equity (Details 3) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Equity [Abstract]
Research and development expenses, net	$ 310	$ 173	$ 502	$ 367
General and administrative	367	154	512	264
Share-based payment expenses, total	$ 677	$ 327	$ 1,014	$ 631

Shareholders Equity (Details Te

Shareholders Equity (Details Textual) $ / shares in Units, $ in Thousands	1 Months Ended			6 Months Ended	12 Months Ended
	Mar. 25, 2020Employees$ / sharesshares	Oct. 28, 2019shares	May 31, 2017$ / sharesshares	Jun. 30, 2020USD ($)$ / sharesshares	Dec. 31, 2019Employeesconsultants$ / sharesshares	Nov. 30, 2017shares
Shareholders Equity (Textual)
Common stock, authorized				60,000,000	60,000,000
Common stock, par value | $ / shares				$ 0.0001
Common stock, issued				23,145,964	22,862,835
Common stock, shares outstanding				23,140,264	22,862,835
Preferred stock, par value | $ / shares				$ 0.0001
Preferred stock, shares authorized				1,000,000
Grant options | $ / shares				$ 914,741
Equity incentive plan, description				On May 5, 2020, the Board of Directors approved the grant of 79,000 options without consideration to four employees, under the 2019 Plan. These options were granted at an exercise price of $5.59 per share with a vesting period of four years. As of June 30, 2020, there are 28,041 shares available for issuance under the 2019 Plan.
Total value of granted options | $				$ 3,900
Issuance of warrants			236,552
Warrants, description				a. 177,414 upon the filing of a patent application covering any Discovered Target or a Product (both as defined in the 2017 License Agreement). b. 118,277 upon achievement of the earlier of the following milestones by the Company: (i) execution of an agreement with a pharmaceutical company with respect to the commercialization of any of the Company's licensed technology or the Consulting IP or a Product (both defined in the 2017 License Agreement) or (ii) the filing of a patent application covering any Discovered Target (as defined in the 2017 License Agreement) or a Product. c. 59,139 upon completion of a Phase 1 clinical trial in respect of a Product (as defined in the 2017 License Agreement).
Public warrants, description				● in whole and not in part; ● at a price of $0.01 per warrant; ● at any time during the exercise period; ● upon a minimum of 30 days' prior written notice of redemption; ● if, and only if, the last sale price of the Company's Common Stock equals or exceeds $16.00 per share for any 20 trading days within a 30-trading day period ending on the third business day prior to the date on which the Company sends the notice of redemption to the warrant holders; and ● if, and only if, there is a current registration statement in effect with respect to the shares of Common Stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption.
Warrants expire years				5 years
License Agreement [Member]
Shareholders Equity (Textual)
Price Per Share | $ / shares			$ 0.0001
Warrants to purchase ordinary shares			591,382
Minimum [Member]
Shareholders Equity (Textual)
Vesting period				3 years
Maximum [Member]
Shareholders Equity (Textual)
Vesting period				4 years
Yeda [Member]
Shareholders Equity (Textual)
Shares of issued warrants						7,615
Founder [Member]
Shareholders Equity (Textual)
Shares of issued warrants						2,974
New Incentive Plan [Member]
Shareholders Equity (Textual)
Common stock, par value | $ / shares					$ 0.0001
Grant options | $ / shares					$ 1,000
Equity incentive plan, description					The aggregate number of shares of Common Stock that may be delivered pursuant to the 2019 Plan will automatically increase on January 1 of each year, commencing on January 1, 2020 and ending on (and including) January 1, 2029, in an amount equal to four percent (4%) of the total number of shares of Common Stock outstanding on December 31 of the preceding calendar year. Notwithstanding the foregoing, the Board of Directors may act prior to January 1 of a given year to provide that there will be no January 1 increase for such year or that the increase for such year will be a lesser number of Common Stock than provided herein.
Stock Options [Member]
Shareholders Equity (Textual)
Purchase of ordinary shares					74,581
Grant options | $ / shares					$ 527,716
Grant approved	814,700				704,669
Employees consideration | Employees	65				22
Non-tradable options					79,630
Consideration consultants | consultants					2
Exercise price | $ / shares	$ 6.21				$ 1.34
BiomX Israel [Member]
Shareholders Equity (Textual)
Exchange for common shares		15,069,058
Shares outstanding, percentage		65.00%
Earnout shares, description					A. 2,000,000 additional shares of the Company’s Common Stock if the daily volume weighted average price of the Company’s Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2022 is greater than or equal to $16.50 per share. B. 2,000,000 additional shares of the Company’s Common Stock if the daily volume weighted average price of the Company’s Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2024 is greater than or equal to $22.75 per share. C. 2,000,000 additional shares of the Company’s Common Stock if the daily volume weighted average price of the Company’s Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2026 is greater than or equal to $29.00 per share.

Related Parties (Details)

Related Parties (Details)	1 Months Ended
	Oct. 31, 2018
Janssen Research & Development, LLC [Member]
Related Parties (Textual)
Research collaboration agreement, description	Under the agreement, BiomX is eligible to receive fees totaling $167 thousand in installments of $50 thousand within 60 days of signing of the agreement, $17 thousand upon completion of data processing, and two installments of $50 thousand each, upon delivery of Signature Phase I of the Final Study Report (both terms defined within the agreement). Unless terminated earlier, this agreement will continue in effect, until 30 days after the parties complete the research program and BiomX provide Janssen with a final study report. The research period started during March 2019 and ended on September 2019. The final report was provided to Janssen in December 2019.

Basic Loss Per Share (Details)

Basic Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Earnings Per Share [Abstract]
Net loss	$ 6,206	$ 3,778	$ 12,107	$ 7,003
Interest accrued on preferred shares (pre-merger - BiomX Israel)		1,231		2,381
Net loss used in the calculation of basic net loss per share	$ 6,206	$ 5,009	$ 12,107	$ 9,384
Net loss per share	$ 0.27	$ 2.50	$ 0.53	$ 4.68
Weighted average number of shares of Common Stock	22,969,075	2,005,047	22,944,482	2,005,047